Clinical trials: Liver Cell Carcinoma Non-resectable
Carcinoma, Hepatocellular
Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer
MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon.
- Trial name
- NCT00034333
- Testing
- MTC-DOX for Injection
- Where
- 29 sites in United States, Austria and 6 more
- Volunteers
- 240 people
- Sponsor
- FeRx
Liver Cancer
Doxorubicin By Infusion or Chemoembolization in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping the cells from dividing.
- Trial name
- NCT00079027
- Testing
- doxorubicin hydrochloride, hepatic artery embolization
- Where
- 10 sites in United Kingdom
- Volunteers
- 280 people
- Sponsor
- University Hospital Birmingham
Hepatocellular Carcinoma Non-resectable
Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab
Aim of the study is to evaluate the efficacy of up-front atezolizumab/ bevacizumab (Atezo/Bev) followed by on-demand selective transarterial chemoembolization (sdTACE) and of initial synchronous treatment with TACE and Atezo/Bev…
- Trial name
- DEMAND (NCT04224636)
- Testing
- Atezolizumab Injection, Bevacizumab Injection
- Where
- 7 sites in Germany
- Volunteers
- 106 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Hepatocellular Carcinoma
Impact of Y90 Radiation Segmentectomy on HCC
The aim of this pilot study is to assess the efficacy of radiation segmentectomy with Theraspheres in patients with unresectable hepatocellular carcinoma that would qualify for thermal ablation as per the BCLC guidelines, but are…
- Trial name
- NCT03248375
- Testing
- Radiation Segmentectomy
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Hepatocellular Carcinoma Non-resectable
TACE Combined With Sorafenib and Tislelizumab for Advanced HCC
This study will evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with sorafenib and tislelizumab in patients with advanced hepatocellullar carcinoma (HCC).
- Trial name
- NCT04599777
- Testing
- TACE combined with sorafenib and tislelizumab
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma (HCC)
A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma
The objective of this clinical trial is to compare the effects of yttrium-90 (SIRT) treatment and hepatic arterial perfusion chemotherapy (HAIC) on progression-free survival (PFS) in patients with potentially resectable HCC in…
- Trial name
- NCT07070076
- Testing
- Yttrium-90, HAIC
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Li Qiang
Hepatocellular Carcinoma
Stereotactic Body Radiation Therapy (SBRT) Hepatocellular Carcinoma (COLD 2)
This study is designed to see whether stereotactic body radiation therapy (SBRT) can reduce tumour size, slow progression of the disease, prolong life and improve quality of life of patients with hepatocellular carcinoma, a…
- Trial name
- NCT00914355
- Testing
- Stereotactic Body Radiation
- Where
- Canada
- Volunteers
- 92 people
- Sponsor
- University Health Network, Toronto
Hepatocellular Cancer, Cholangiocarcinoma
Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases
The main purpose of this study is to determine if high doses of radiation using proton beam can be given safely with low and acceptable side effects.
- Conditions
- Hepatocellular Cancer, Cholangiocarcinoma, Hepatic Metastases
- Trial name
- NCT00465023
- Testing
- Proton Beam Radiation
- Volunteers
- 16 people
- Sponsor
- Massachusetts General Hospital
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC)
FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma
This study is a prospective, multicenter Phase II trial evaluating a personalized treatment strategy for patients with unresectable hepatocellular carcinoma (HCC).
- Conditions
- Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC), Liver Cancer Adult
- Trial name
- FAD-HCC-001 (NCT07314372)
- Testing
- Camrelizumab Plus Apatinib, TACE Plus Camrelizumab and Apatinib
- Where
- China
- Volunteers
- 86 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Breast Cancer, Lung Cancer
Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer
This is a multicenter, open-label, randomized, controlled study to test the hypothesis that ePRO monitoring added to usual care helps prolong OS or maintain and improve HRQoL in patients with unresectable advanced cancers or…
- Conditions
- Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer
- Trial name
- NCT05931445
- Testing
- e-PRO monitoring
- Where
- Japan
- Volunteers
- 500 people
- Sponsor
- Comprehensive Support Project for Oncology Research
Hepatocellular Carcinoma
Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
This study is an open-label, multicenter, single-arm Phase II clinical study to evaluate the effectiveness of Cadonilimab(AK104) in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment…
- Trial name
- NCT06406634
- Testing
- Cadonilimab, Lenvatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hunan Cancer Hospital
Hepatocellular Carcinoma
A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)
This is a multi-center,open-label study to evaluate the efficacy and safety of anti-PD-1 antibody AK105 plus anlotinib hydrochloride in the first-line treatment of patients with unresectable hepatocellular carcinoma.
- Trial name
- NCT04172571
- Testing
- AK105, Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Akeso
Unresectable or Metastatic Hepatocellular Carcinoma
Temsirolimus as Second-line Therapy in HCC
The purpose of this study is to evaluate the activity of temsirolimus in patients who have advanced hepatocellular carcinoma (HCC) and have been treated with one previous chemotherapy or biologic therapy like sorafenib, but have…
- Trial name
- NCT01567930
- Testing
- Temsirolimus
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Tennessee Cancer Institute
Hepatocellular Carcinoma
A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Phase II open label, multicenter study to evaluate the efficacy and safety of AK112 (PD-1/VEGF Bispecific) in patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT05432492
- Testing
- AK112
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Akeso
Advanced Adult Hepatocellular Carcinoma, Non-Resectable Hepatocellular Carcinoma
Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery
This phase I/II trial studies the side effects and best dose of tivozanib and to see how well it works in treating patients with liver cancer that has spread to other parts of the body or cannot be removed by surgery.
- Trial name
- NCT01835223
- Testing
- Tivozanib (1mg), Tivozanib (1.5mg)
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Roswell Park Cancer Institute
Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of dasatinib in treating patients with solid tumors or lymphomas that are metastatic or cannot be removed by surgery.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia, Adult Hepatocellular Carcinoma, Adult Nasal Type Extranodal NK/T-Cell Lymphoma
- Trial name
- NCT00608361
- Testing
- Dasatinib, Pharmacological Study
- Where
- 23 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
HepatoCellular Carcinoma
HAIC of Oxaliplatin, and 2400 mg/m² 5-fu vs HAIC of Oxaliplatin, and 1200 mg/m² 5-fu for Unresectable HCC: a Randomised Phase 3 Non-inferiority Trial
Hepatic artery infusion of oxaliplatin, leucovorin and 2400 mg/m² fluorouracil is effective in hepatocellular carcinoma. However, SILIUS study showed that sorafenib plus hepatic artery infusion of cisplatin and fluorouracil did…
- Trial name
- NCT04667351
- Testing
- 2400 mg/m² 5-fu, 1200 mg/m² 5-fu
- Where
- 3 sites in China
- Volunteers
- 400 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Liver Cancer
Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery
The primary objective will be to assess progression-free survival (PFS) measured at 16 weeks following initiation of therapy with the combination of Avastin and erlotinib in patients with unresectable hepatocellular carcinoma…
- Trial name
- NCT00242502
- Testing
- Bevacizumab (Avastin), Erlotinib
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma, Solid Tumor
A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene
This is a Phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients…
- Conditions
- Hepatocellular Carcinoma, Solid Tumor, Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent
- Trial name
- MYCHELANGELO I (NCT05497453)
- Testing
- OTX-2002, Tyrosine kinase inhibitor One, Tyrosine kinase inhibitor Two
- Where
- 15 sites in United States, Hong Kong and 3 more
- Volunteers
- 24 people
- Sponsor
- Omega Therapeutics